CYMA News Alert Cymabay Therapeutics (CYMA) 6.4500 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cymabay Therapeutics (CYMA) 6.4500 $CYMA

CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"
Marketwire - Mon Jun 16, 8:02AM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Wednesday, June 18, 2014 under the symbol "CBAY". The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol "CYMA", until the market close on Tuesday, June 17, 2014.

CymaBay reports launch of Phase 2b study of arhalofenate in gout patients
M2 - Thu Mar 27, 5:19AM CDT
Biopharmaceutical company CymaBay Therapeutics (OTC BB:CYMA) said on Wednesday that it has randomized the first patient under its Phase 2b clinical trial of arhalofenate for for the treatment of gout, a chronic, progressive rheumatic disease.

CymaBay Initiates Arhalofenate Phase 2b Gout Study
Marketwire - Wed Mar 26, 3:21PM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing therapies addressing unmet medical needs in metabolic disease, today announced that it has randomized the first patient in a Phase 2b clinical trial of arhalofenate (MBX-102). Arhalofenate is a dual acting product candidate for the treatment of gout that is targeted to lower serum uric acid (sUA) and reduce the incidence of flares.

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer
Marketwire - Mon Mar 03, 8:02AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs in metabolic diseases, today announced that Dr. Pol Boudes has joined the company as Chief Medical Officer. Dr. Boudes brings extensive clinical development experience to CymaBay, including expertise in all phases of clinical trial design and execution.

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences
Marketwire - Tue Feb 25, 8:05AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.

Mixed Dyslipidemia - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/85sdh6/mixed) has announced the addition of the "Mixed Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Mixed Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Mixed Dyslipidemia. - A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mixed Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mixed Dyslipidemia Overview Therapeutics Development Pipeline Products for Mixed Dyslipidemia - Overview Pipeline Products for Mixed Dyslipidemia - Comparative Analysis Mixed Dyslipidemia - Therapeutics under Development by Companies Mixed Dyslipidemia - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Mixed Dyslipidemia - Products under Development by Companies Mixed Dyslipidemia - Companies Involved in Therapeutics Development Mixed Dyslipidemia - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles evolocumab - Drug Profile Product Description Mechanism of Action R&D Progress bococizumab - Drug Profile Product Description Mechanism of Action R&D Progress INSUPR-001 DR - Drug Profile Product Description Mechanism of Action R&D Progress MBX-8025 - Drug Profile Product Description Mechanism of Action R&D Progress PRC-4016 - Drug Profile Product Description Mechanism of Action R&D Progress CAT-2003 - Drug Profile Product Description Mechanism of Action R&D Progress MAT-9001 - Drug Profile Product Description Mechanism of Action R&D Progress Mixed Dyslipidemia - Recent Pipeline Updates Mixed Dyslipidemia - Dormant Projects Mixed Dyslipidemia - Discontinued Products Mixed Dyslipidemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Pfizer Inc. Pronova BioPharma ASA Intas Pharmaceuticals Ltd. Catabasis Pharmaceuticals, Inc. Matinas BioPharma, Inc. CymaBay Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/85sdh6/mixed About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link
Marketwire - Fri Jan 24, 8:00AM CST
CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 39

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 232

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 216

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 147

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 0

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 229

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Launch of RM11, a Game-Changer for Creators

Updated Category News Views 451

Introducing RM11: A New Era for Creators RM11 is an innovative digital platform crafted specifically for creators, prioritizing their needs and ensuring they keep more of their hard-earned money. With a comprehensive payout model allowing creators to retain 90% of earnings, RM11 focuses on fostering a vibrant ecosystem where creators thrive without excessive fees or...

Continue Reading
Tyfast Energy Secures Grant to Enhance Lithium-Ion Battery Tech

Updated Category News Views 174

Tyfast Energy Secures Funding for Advanced Battery Development Tyfast Energy, an innovative battery materials company, has achieved a significant milestone by securing a $100,000 grant aimed at enhancing its development of lithium-ion batteries. This funding, provided by the National Science Foundation's Energy Storage Engine, is expected to expedite the advancement of...

Continue Reading
DMG Blockchain Solutions Sets Stage for AI Growth with MOU

Updated Category News Views 285

DMG Blockchain Solutions Expands into Generative AI DMG Blockchain Solutions Inc. has recently made headlines with its agreement to acquire a 10-megawatt prefabricated data center. This significant advancement positions DMG as a key player in the growing field of Generative Artificial Intelligence (Gen AI). The memorandum of understanding (MOU) signifies a strategic step...

Continue Reading
EPAM Systems Achieves Steady Growth in 2024 Financial Results

Updated Category News Views 205

Financial Overview of EPAM Systems for 2024 EPAM Systems, Inc. (NYSE: EPAM), a premier digital transformation and product engineering company, has reported commendable financial results for the fourth quarter and full year of 2024. The company displayed resilience in its growth amid a changing economic landscape, showcasing a 7.9% increase in revenues year-over-year in...

Continue Reading
Carvana Stock Surges After Bullish Power Inflow Indicator

Updated Category News Views 242

Carvana Stock Gains After Bullish Indicator Carvana Co (NYSE: CVNA) experienced an exciting uptick in its stock price following a noteworthy signal known as the Power Inflow. This indicator, closely monitored by traders focused on order flow analytics, reflects significant shifts in buying momentum, particularly from both institutional and retail investors. The Power...

Continue Reading